Lv1
88 积分 2024-01-19 加入
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study
3个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
3个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
8个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
11个月前
已完结
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
11个月前
已完结
Well-differentiated fetal adenocarcinoma presenting with cutaneous metastases
1年前
已完结
[Experience with High-grade Fetal Lung Adenocarcinoma;Report of a Case]
1年前
已关闭
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
1年前
已完结
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
1年前
已完结
[Introduction to the 9
1年前
已完结